Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff; Novo searching for new CEO with Sørensen out as soon as next year;

> Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Editor's Corner

> Novo searching for new CEO with Sørensen out as soon as next year. More

> Roche builds CLL case for Gazyva in two-horse race with GSK. Article

> Actavis goes 1-for-2 with FDA as regulators knock blood pressure combo. Story

> Sen. Warren urges CMS to get on board, encourage UDI info in insurance claims forms. News

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.